Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ABP 980 with oxaliplatin-based first-line chemotherapy in HER2-positive advanced gastric or gastroesophageal junction cancer
2019-004357-86Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Started Aug 2021; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2019-004357-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004357-86.